TDP-43 loss of function drives aberrant splicing in Parkinson's disease
Demonstrated that TDP-43 loss of function drives aberrant splicing events in Parkinson's disease.
Demonstrated that TDP-43 loss of function drives aberrant splicing events in Parkinson's disease.
Demonstrated that AAV-delivered chimeric TDP-43 repressor (CTR) achieves broad brain biodistribution, restores TDP-43 splicing function, rescues neurons, and mitigates FTD-like …
TDP-43 depletion exacerbates tauopathy-dependent brain atrophy by sensitizing neurons to caspase 3-mediated tau cleavage in a multiple etiology dementia mouse model.
Conference abstract presented at ASGCT 2024 on validating TDP-43 splicing repression as a therapeutic strategy for ALS and FTD.
Meta-analysis and systematic review examining the association between retina thinning and hippocampal atrophy in Alzheimer's disease and MCI.
Meta-analysis of TCM syndrome elements in amyotrophic lateral sclerosis.
Discussion on digital approaches for preserving and inheriting the clinical experiences of renowned TCM practitioners.
Systematic review and meta-analysis evaluating the safety and efficacy of edaravone in ALS patients.
Identified novel disease stage-specific microglia subtypes induced by synergistic Aβ and tau pathologies.
Meta-analysis of TCM combined with hydroxychloroquine sulfate for Sjogren's syndrome treatment.